...
首页> 外文期刊>Acta Histochemica: Zeitschrift fur Histologische Topochemie >Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
【24h】

Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.

机译:环氧合酶2(COX2)和p53蛋白的表达在乳腺癌中是相互依赖的,但与临床病理替代亚型,肿瘤侵袭性和患者生存率无关。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In the last decade, different molecular subtypes of breast cancer have been proposed. Although displaying appreciable association with disease prognosis and the prognostic value of cytotoxic and endocrine therapeutic modalities, the subtypes seem to fail at completely explaining disease behavior and response to treatment. Molecules such as those of the cyclocooxigenase (COX) family, currently composed of three entities (COX 1, 2 and 3) have been shown to be associated with breast carcinogenesis, and the analysis of p53 expression in breast tumors may also offer some additional prognostic clues. Our study is aimed at assessing COX2 and p53 expression in these clinico-pathological surrogate subtypes, and to evaluate whether the expression of these molecules can help further explain the variability in prognosis still found within the clinico-pathological subtypes groups of breast cancer.
机译:在过去的十年中,已经提出了乳腺癌的不同分子亚型。尽管与疾病的预后以及细胞毒性和内分泌治疗方式的预后价值显示出可观的联系,但这些亚型似乎无法完全解释疾病的行为和对治疗的反应。分子,例如目前由三个实体(COX 1、2和3)组成的环氧合酶原(COX)家族的分子已被证明与乳腺癌的致癌作用有关,对乳腺癌中p53表达的分析也可能提供其他预后线索。我们的研究旨在评估这些临床病理替代亚型中的COX2和p53表达,并评估这些分子的表达是否可以帮助进一步解释乳腺癌临床病理亚型组中仍存在的预后差异。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号